In a phase I clinical trial, CD40 agonist mAb therapy in combination with gemcitabine resulted in tumor response in 19% of patients with unresectable chemotherapy naïve pancreatic cancer.62 Tumor biopsies from these patients showed a dearth of TIL and an abundance of tumor infiltrating macrophages.62 A second phase I study is aimed at studying the combination of anti‐CD40 therapy with nab‐paclitaxel and gemcitabine in pancreatic cancer and is currently enrolling (Table 1). The gene discussed is CD40; the disease is neoplasm.